Clearmind Strengthens Global IP Portfolio For MEAI With New Patent Filing In South Korea To Support Its Use In Depression Treatment

Clearmind Medicine Inc., a clinical-stage biotechnology company focused on developing novel neuroplastogen-derived therapeutics to address major under-treated health conditions, has announced the filing of a new patent application in South Korea. The patent covers compositions containing the company’s proprietary compound, 5-methoxy-2-aminoindane (MEAI), for the treatment of depression.

This latest filing further strengthens Clearmind’s expanding global intellectual property portfolio for MEAI, a unique non-hallucinogenic neuroplastogen designed to modulate serotonin pathways, promote neuroplasticity, and alleviate depressive symptoms without the psychoactive effects commonly associated with traditional psychedelic compounds. The addition of South Korea to its list of protected jurisdictions marks an important step in securing broad international protection for MEAI’s therapeutic applications.

According to the World Health Organization, major depressive disorder affects more than 280 million people globally and remains one of the leading causes of disability. Despite its prevalence, innovative treatment options for depression are still limited, and a significant number of patients fail to respond adequately to conventional antidepressant medications.

Preclinical studies conducted by Clearmind have shown MEAI’s potential to improve mood regulation and reduce anhedonia, a core symptom of depression characterized by the loss of interest or pleasure. These results suggest that MEAI could offer a differentiated therapeutic approach for patients who do not benefit from standard treatments. The company’s growing patent portfolio now includes protections across multiple regions for MEAI’s use in various mental health and addiction disorders, reinforcing its strategic focus on developing next-generation neuroactive compounds.

Commenting on the announcement, Adi Zuloff-Shani, PhD, Chief Executive Officer of Clearmind Medicine, stated, “This patent filing marks another important milestone in expanding our intellectual property protection and advancing MEAI as a novel, next-generation treatment for depression. As we continue to broaden our global footprint, we are also preparing for the next stages of clinical development and commercialization to potentially bring our non-hallucinogenic neuroplastogen therapies to patients worldwide.”

Through continued innovation and global patent expansion, Clearmind Medicine aims to establish MEAI as a leading candidate in the evolving field of neuroplasticity-based treatments for mental health disorders.